Siglec receptors as new immune checkpoints in cancer

Michal A Stanczak; Heinz Läubli

doi:10.1016/j.mam.2022.101112

Siglec receptors as new immune checkpoints in cancer

Mol Aspects Med. 2023 Apr:90:101112. doi: 10.1016/j.mam.2022.101112. Epub 2022 Aug 7.

Authors

Michal A Stanczak¹, Heinz Läubli²

Affiliations

¹ The Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, 21287, USA.
² Laboratory for Cancer Immunotherapy, Department of Biomedicine, University of Basel, Division of Oncology, University Hospital Basel, Switzerland. Electronic address: heinz.laeubli@unibas.ch.

PMID: 35948467
DOI: 10.1016/j.mam.2022.101112

Abstract

Cancer immunotherapy in the form of immune checkpoint inhibitors and cellular therapies has improved the treatment and prognosis of many patients. Nevertheless, most cancers are still resistant to currently approved cancer immunotherapies. New approaches and rational combinations are needed to overcome these resistances. There is emerging evidence that Siglec receptors could be regarded as new immune checkpoints and targets for cancer immunotherapy. In this review, we summarize the experimental evidence supporting Siglec receptors as new immune checkpoints in cancer and discuss their mechanisms of action, as well as current efforts to target Siglec receptors and their interactions with sialoglycan Siglec-ligands.

Keywords: Cancer immunotherapy; Immune checkpoint inhibitor; Innate immunity; Monoclonal antibodies; Sialic acid; Sialidase; T cells.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Immune Checkpoint Proteins
Immunotherapy
Neoplasms* / therapy
Sialic Acid Binding Immunoglobulin-like Lectins* / genetics

Substances

Sialic Acid Binding Immunoglobulin-like Lectins
Immune Checkpoint Proteins